WQWenchao Qu

Wenchao Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenchao Qu has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel [67Cu]Cu-Labeled 4- p -(Tolyl)butyric Acid-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Glycine and Polyethylene Glycol Linkers for Melanoma Targeting

    by Zheng Qiao, Jingli Xu, Jing Wang, Megan Schulte, Fabio Gallazzi, Adrian F. Howansky, Wenchao Qu, Charles J. Smith, Yubin Miao

    This study managed to examine how the 4-p-(tolyl)butyric acid (p-TBA) albumin binder and the aspartic acid linker affect the tumor targeting and biodistribution properties of [67Cu]Cu-labeled p-TBA-conjugated alpha-melanocyte-stimulating hormone (α-MSH) peptides. p-TBA was attached to 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Lys-Gly-Gly-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH2 (NOTA-Lys-GGNle-CycMSHhex) and NOTA-Lys-PEG2Nle-CycMSHhex with or without the Asp linker to generate NOTA-Lys(p-TBA/Asp-p-TBA)-GGNle-CycMSHhex and NOTA-Lys(p-TBA/Asp-p-TBA)-PEG2Nle-CycMSHhex. The melanocortin-1 receptor (MC1R) binding affinities of the designed peptides were determined on B16/F10 melanoma cells. The biodistribution properties of [67Cu]Cu-NOTA-Lys(p-TBA/Asp-p-TBA)-GGNle-CycMSHhex and [67Cu]Cu-NOTA-Lys(p-TBA/Asp-p-TBA)-PEG2Nle-CycMSHhex were evaluated on B16/F10 melanoma-bearing C57BL/6 mice at 2 h post-injection to select a lead peptide. Then, the melanoma targeting and imaging properties of [67Cu]Cu-NOTA-Lys(Asp-p-TBA)-PEG2Nle-CycMSHhex were determined on B16/F10 melanoma-bearing C57BL/6 mice. The IC50 values of NOTA-Lys(p-TBA/Asp-p-TBA)-GGNle-CycMSHhex and NOTA-Lys(p-TBA/Asp-p-TBA)-PEG2Nle-CycMSHhex were 0.26 ± 0.04, 0.54 ± 0.03, 0.46 ± 0.08, and 0.32 ± 0.04 nM, respectively. [67Cu]Cu-NOTA-Lys(Asp-p-TBA)-PEG2Nle-CycMSHhex was selected as a lead peptide due to its highest tumor/kidney and tumor/liver uptake ratios among the [67Cu]Cu-peptides at 2 h post-injection. The B16/F10 melanoma uptake of [67Cu]Cu-NOTA-Lys(Asp-p-TBA)-PEG2Nle-CycMSHhex was 29.31 ± 3.22, 39.05 ± 1.38, 25.07 ± 2.03, and 11.77 ± 1.61% ID/g at 0.5, 2, 4, and 24 h post-injection, respectively. The B16/F10 melanoma lesions were clearly visualized by SPECT/CT using [67Cu]Cu-NOTA-Lys(Asp-p-TBA)-PEG2Nle-CycMSHhex as an imaging probe at 2 h post-injection. The utilization of p-TBA as an albumin binder prolonged the blood circulation and enhanced the tumor uptake of [67Cu]Cu-Asp-p-TBA-PEG as compared to [67Cu]Cu-NOTA-PEG2Nle-CycMSHhex without an albumin-binding moiety. The Asp linker expedited the blood clearance of [67Cu]Cu-Asp-p-TBA-PEG as compared to [67Cu]Cu-p-TBA-PEG. The combination of p-TBA, Asp, and PEG linkers resulted in the highest tumor/blood, tumor/kidney, and tumor/liver uptake ratios of [67Cu]Cu-Asp-p-TBA-PEG among the designed [67Cu]Cu-labeled p-TBA-conjugated CycMSHhex peptides. The favorable tumor targeting and blood clearance properties of [67Cu]Cu-Asp-p-TBA-PEG underscore its potential for future melanoma therapy.


  • Open Access

    Deuterium- and Fluorine-18-Labeled Glutamine─a PET Imaging Agent with Enhanced In Vivo Stability

    by Hari K. Akula, Bao Hu, Jaclyn Brunner, Kaixuan Li, Lemise Saleh, Paul Vaska, Wenchao Qu

    Deuterium and fluorine-18 dual-isotope-labeled fluoroglutamine, (2S,4R)-[4-18F-3,3,4-d3]­fluoroglutamine (4-[18F]­FGln-d3), was designed, synthesized, and biologically evaluated for its potential as a novel glutamine metabolic imaging agent with improved in vivo stability. The tetradeuterated homoserine 11 intermediate was first synthesized via a six-step synthetic pathway, including a chiral HPLC separation process. Next, (2S,4S)-tosylate precursor 14 was prepared following the reference-reported method, and 4-[18F]­FGln-d3 was successfully prepared using a semiautomated production process. After that, a head-to-head comparison of 4-[18F]­FGln-d3 with its parent compound 4-[18F]­FGln including in vitro cell uptake and in vivo murine animal imaging studies illustrated that the new tracer 4-[18F]­FGln-d3 has a similar cell uptake manner and comparable tumor uptake and tumor-to-muscle ratio as 4-[18F]­FGln, but moderately decreased radioactivity bone uptake at 120 min postinjection. Overall, the preliminary data from this research indicate the better in vivo stability of 4-[18F]­FGln-d3 compared with its counterpart 4-[18F]­FGln, which warrants further investigation of this radiotracer as the new PET imaging agent with enhanced stability for probing the glutamine metabolism in vivo.


  • The Potential Utility of (2S,4R)-4-[18F]fluoroglutamine as a Novel Metabolic Imaging Marker for Inflammation Explored by Rat Models of Arthritis and Paw Edema

    by Min-Jeong Kim, Hari K. Akula, Jocelyn Marden, Kaixuan Li, Bao Hu, Paul Vaska, Wenchao Qu

    Purpose (2S,4R)-4-[18F]fluoroglutamine ([18F]FGln) is a promising metabolic imaging marker in cancer. Based on the fact that major inflammatory cells are heavily dependent on glutamine metabolism like cancer cells, we explored the potential utility of [18F]FGln as a metabolic imaging marker for inflammation in two rat models: carrageenan-induced paw edema (CIPE) and collagen-induced arthritis (CIA). Procedures The CIPE model (n = 4) was generated by injecting 200 µL of 3% carrageenan solution into the left hind paw three hours before the PET. The CIA model (n = 4) was generated by injecting 200 µg of collagen emulsion subcutaneously at the tail base 3–4 weeks before the PET. A qualitative scoring system was used to assess the severity of paw inflammation. After a CT scan, 15.7 ± 4.9 MBq of [18F]FGln was injected via the tail vein, followed by a dynamic micro-PET scan for 90 min under anesthesia with isoflurane. The standard uptake value of [18F]FGln was measured by placing a volume of interest in each paw. The non-injected right hind paws of the CIPE model rats served as controls for both models. The paws with CIA were pathologically examined after PET. Results The CIPE models showed a trend toward higher uptake in the injected paw compared to the non-injected paw (P = 0.068). In CIA models, uptake in the paws with severe inflammation was significantly higher than the controls (P = 0.011), while that with mild and no inflammation was slightly higher (33%) and lower (-7%), respectively. Combined overall, the [18F]FGln uptake in CIA showed a significant positive correlation with inflammation severity (r = 0.88, P = 0.009). The pathological findings confirmed profound inflammation in CIA. Conclusions [18F]FGln uptake was increased in both acute and chronic inflammation, and the uptake level was significantly correlated with the severity, suggesting its potential utility as a novel metabolic imaging marker for inflammation.


  • Preclinical Positron Emission Tomography (PET) of Prosthetic Joint Infection Using a Nitro-Prodrug of 2-[18F]F-p-Aminobenzoic Acid ([18F]F-PABA)

    by Alyssa C. Pollard-Kerning, Kaixuan Li, Yong Li, Shin Hye Ahn, Mingqian Wang, Melike Akoglu, Eduardo Bravo, Francesca DelloRusso, Hari K. Akula, Wenchao Qu, et al.

    Deep-seated bacterial infections are difficult to detect and diagnose due to the lack of specific clinical imaging modalities. Therefore, the bacteria-specific positron emission tomography radiotracer 2-[18F]fluoro-4-nitrobenzoic acid ([18F]FNB) was developed, which is reduced to 2-[18F]fluoro-4-aminobenzoic acid ([18F]F-PABA) by bacterial nitroreductases and has improved pharmacokinetics compared to the parent compound. PET imaging demonstrated that the uptake of 2-[18F]fluoro-4-nitrobenzoic acid in a clinically relevant Staphylococcus aureus prosthetic joint infection model was up to ∼4-fold higher in the infected joint compared to the contralateral joint. 2-[18F]Fluoro-4-nitrobenzoic acid was also able to distinguish infection from inflammation in a surgical inflammation model. Based on the mouse radiation dosimetry results, the calculated effective dose of 2-[18F]fluoro-4-nitrobenzoic acid was well below the whole-body radiation dose limit established by the Food and Drug Administration for humans. In addition, no treatment-related microscopic changes in organ histopathology were observed in a mouse acute toxicity study. Overall, these data suggest that 2-[18F]fluoro-4-nitrobenzoic acid is a specific and effective imaging agent for noninvasively diagnosing prosthetic joint infections.


  • Biological Evaluation of d-[18F]Fluoroalanine and d-[18F]Fluoroalanine-d3 as Positron Emission Tomography Imaging Tracers for Bacterial Infection

    by Kaixuan Li, Jinnette Tolentino Collado, Jocelyn A. Marden, Alyssa C. Pollard, Shuwen Guo, Peter J. Tonge, Wenchao Qu

    D-Amino acids such as d-alanine are substrates for bacterial peptidoglycan biosynthesis and are selectively taken up by bacteria and not mammalian cells. Consequently, d-amino acid metabolism is an attractive target for antibiotic discovery and the development of bacteria-specific imaging agents. d-Fluoroalanine and the deuterium-labeled analogue fludalanine (MK641) were originally explored as antibiotics by Merck but failed in clinical trials due to unaccepted toxicity. Herein, we synthesized a fluorine-18 labeled d-fluoroalanine, d-3-[18F]fluoroalanine (d-[18F]FAla), and its deuterated analogue, d-3-[18F]fluoroalanine-d3 (d-[18F]FAla-d3), and evaluated their capability to image bacterial infection. Both d-[18F]FAla and d-[18F]FAla-d3 can accumulate up to 0.64-0.78% ID/cc in the infectious area at 15 min postinjection. Despite the reduction of in vivo defluorination not being observed for deuterated 18F-labeled d-fluoroalanine, these radiolabeled d-alanine analogues were able to differentiate bacterial infection from sterile inflammation in a soft-tissue model of S. aureus infection.


  • Synthesis and Biological Evaluation of Fluorine-18 and Deuterium Labeled l-Fluoroalanines as Positron Emission Tomography Imaging Agents for Cancer Detection

    by Kaixuan Li, Alexa L. Gilberti, Jocelyn A. Marden, Hari K. Akula, Alyssa C. Pollard, Shuwen Guo, Bao Hu, Peter J. Tonge, Wenchao Qu

    To fully explore the potential of 18F-labeled l-fluoroalanine for imaging cancer and other chronic diseases, a simple and mild radiosynthesis method has been established to produce optically pure l-3-[18F]fluoroalanine (l-[18F]FAla), using a serine-derivatized, five-membered-ring sulfamidate as the radiofluorination precursor. A deuterated analogue, l-3-[18F]fluoroalanine-d3 (l-[18F]FAla-d3), was also prepared to improve metabolic stability. Both l-[18F]FAla and l-[18F]FAla-d3 were rapidly taken up by 9L/lacZ, MIA PaCa-2, and U87MG cells and were shown to be substrates for the alanine-serine-cysteine (ASC) amino acid transporter. The ability of l-[18F]FAla, l-[18F]FAla-d3, and the d-enantiomer, d-[18F]FAla-d3, to image tumors was evaluated in U87MG tumor-bearing mice. Despite the significant bone uptake was observed for both l-[18F]FAla and l-[18F]FAla-d3, the latter had enhanced tumor uptake compared to l-[18F]FAla, and d-[18F]FAla-d3 was not specifically taken up by the tumors. The enhanced tumor uptake of l-[18F]FAla-d3 compared with its nondeuterated counterpart, l-[18F]FAla, warranted the further biological investigation of this radiotracer as a potential cancer imaging agent.


  • An improved synthesis of [18F]VAT and its precursor

    by Bao Hu, Hari K. Akula, Doyoung Noh, Yiu Fung Mui, Mark Slifstein, Ramin Parsey, Wenchao Qu

    The vesicular acetylcholine transporter (VAChT) in the brain is an important presynaptic cholinergic biomarker, and neuroimaging studies of VAChT may provide in vivo information about psychiatric and neurologic conditions including Alzheimer's disease that are not accessible by other methods. The 18F‐labeled radiotracer, ((‐)‐(1‐(‐8‐(2‐[18F]fluoroethoxy)‐3‐hydroxy‐1,2,3,4‐tetrahydronaphthalen‐2‐yl)piperidin‐4‐yl)(4‐fluorophenyl)‐methanone ([18F]VAT, 1), was reported as a selective and high affinity ligand for the in vivo imaging of VAChT. The synthesis of [18F]VAT has been reported in a two‐step procedure with total 140 min, which includes preparation of 2‐[18F]fluoroethyltosylate and alkylation of benzovesamicol (‐)‐5 precursor with this radiosynthon using two different automated production modules consecutively. A multiple step synthetic route was employed for the synthesis of stereospecific precursor benzovesamicol (‐)‐5, which is difficult to be adapted for scale‐up. To make the production of this tracer more amenable for clinical imaging, we present an improved total synthesis protocol to attain [18F]VAT: (1) a tosylethoxy group being pre‐installed tosylate precursor (‐)‐8 is synthesized to render a simple one‐step radiofluorination under mild conditions; (2) The key optically active intermediate benzovesamicol (‐)‐5 was obtained via the regio‐ and enantio‐enriched ring‐opening amination of meso‐epoxide 3 with 4‐phenylpiperidine derivative 2 under catalysis of a chiral salenCo(III) catalyst 4b, which dramatically simplifies the synthetic route of the tosylate precursor (‐)‐8. [18F]VAT 1 was prepared within ~65 min with desired chemical and radiochemical purities, via a fully automated procedure, using a commercial PET tracer production module. The final drug product was obtained as a sterile, pyrogen‐free solution that conforms United States Pharmacopeia (USP) requirements.


  • Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase

    by Kaixuan Li, Mingqian Wang, Melike Akoglu, Alyssa C. Pollard, John B. Klecker, Patricia Alfonso, Ana Corrionero, Niall Prendiville, Wenchao Qu, Matthew F. L. Parker, et al.

    Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases. To aid in the discovery and development of BTK inhibitors and improve clinical diagnoses, we have developed a positron emission tomography (PET) radiotracer based on a selective BTK inhibitor, remibrutinib. [18F]PTBTK3 is an aromatic, 18F-labeled tracer that was synthesized in 3 steps with a 14.8 +/- 2.4% decay-corrected radiochemical yield and >= 99% radiochemical purity. The cellular uptake of [18F]PTBTK3 was blocked up to 97% in JeKo-1 cells using remibrutinib or non-radioactive PTBTK3. [18F]PTBTK3 exhibited renal and hepatobiliary clearance in NOD SCID (non obese diabetic/severe combined immunodeficiency) mice, and the tumor uptake of [18F]PTBTK3 in BTK-positive JeKo-1 xenografts (1.23 +/- 0.30% ID/cc) was significantly greater at 60 min post injection compared to the tumor uptake in BTK-negative U87MG xenografts (0.41 +/- 0.11% ID/cc). In the JeKo-1 xenografts, tumor uptake was blocked up to 62% by remibrutinib, indicating the BTK-dependent uptake of [18F]PTBTK3 in tumors.


  • Open Access

    Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography

    by James M. Kelly, Thomas M. Jeitner, Nicole N. Waterhouse, Wenchao Qu, Ethan J. Linstad, Banafshe Samani, Clarence Williams, Anastasia Nikolopoulou, Alejandro Amor-Coarasa, Stephen G. DiMagno, et al.

    Cancer cells require lipids to fulfill energetic, proliferative, and signaling requirements. Even though these cells can take up exogenous fatty acids, the majority exhibit a dependency on de novo fatty acid synthesis. Fatty acid synthase (FASN) is the rate-limiting enzyme in this process. Expression and activity of FASN is elevated in multiple cancers, where it correlates with disease progression and poor prognosis. These observations have sparked interest in developing methods of detecting FASN expression in vivo. One promising approach is the imaging of radiolabeled molecular probes targeting FASN by positron emission tomography (PET). However, although [11C]acetate uptake by prostate cancer cells correlates with FASN expression, no FASN-specific PET probes currently exist. Our aim was to synthesize and evaluate a series of small molecule triazolones based on GSK2194069, an FASN inhibitor with IC50 = 7.7 ± 4.1 nM, for PET imaging of FASN expression. These triazolones were labeled with carbon-11 in good yield and excellent radiochemical purity, and binding to FASN-positive LNCaP cells was significantly higher than FASN-negative PC3 cells. Despite these promising characteristics, however, these molecules exhibited poor in vivo pharmacokinetics and were predominantly retained in lymph nodes and the hepatobiliary system. Future studies will seek to identify structural modifications that improve tumor targeting while maintaining the excretion profile of these first-generation 11C-methyltriazolones.


  • [11C]HCN Radiochemistry: Recent Progress and Future Perspectives

    by Youwen Xu, Wenchao Qu

    Positron emission tomography (PET) is a unique non‐invasive imaging tool for studying in vivo biological processes. It utilizes short‐lived positron emitter labeled organic molecules to study biological events in real‐time. To incorporate the positron emitter into a molecule of biological interest, radioactive synthons are developed to facilitate radiolabeling chemistry. In addition to 11C‐methylation with [11C]CH3I/[11C]CH3OTf, 11C‐carbonylation with [11C]CO, and 11C‐carboxylation of organometallic reagents with [11C]CO2, 11C‐cyanation with [11C]HCN is another frequently used 11C‐labeling methodology. It can lead to the generation of [11C]organo‐nitriles, [carbonyl‐11C]carboxylic acids, [carbonyl‐11C]aldehydes, [carbonyl‐11C]amides, [11C]alkyl amines, [tetrazoyl‐11C]tetrazoles, [11C]CN‐containing heterocycles, etc. This review recognizes the important roles of 11C‐cyanation reactions with the emphasis of recent advances, along with the discussion of molar activities (Am) of [11C]HCN based radiotracers and prompts for future potential [11C]cyanide based radiotracer development.